Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 112 clinical trials
  • 0 views
  • 19 Jun, 2021
  • 30 locations
RBN-2397 in Combination With Pembrolizumab in Patients With SCCL

RBN-2397 inhibits PARP7, an enzyme that is switched on by cancer stresses, such as the toxins in cigarette smoke. Cancer cells use PARP7 to hide from the immune system by stopping the cell from sending a signal (Type 1 interferon) that tells the immune system that something is wrong and …

  • 0 views
  • 13 Jul, 2022
  • 8 locations
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation

chemotherapy for patients with surgically resectable stage IIA - IIIB (T3-T4/N2) (based on AJCC 8th edition), non-squamous NSCLC with a KRAS p.G12C mutation. The primary objective of the study is to determine

KRAS
carboplatin
pemetrexed
lung carcinoma
lung cancer
  • 0 views
  • 22 Apr, 2022
  • 1 location
Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer

A Phase 1/2, Open-Label Study of ADXS-503 Alone and in Combination with Pembrolizumab in Subjects with Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer

squamous non-small cell lung cancer
measurable disease
alopecia
endobronchial ultrasound
systemic therapy
  • 14 views
  • 25 Mar, 2022
  • 9 locations
Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901

To evaluate the efficacy and safety of Pembrolizumab + Pemetrexed in elderly patients with non-squamous non-small cell lung cancer with Programmed cell death (PD) -ligand1 (L1) tumor proportion

pemetrexed
metastasis
monoclonal antibodies
lung cancer
measurable disease
  • 0 views
  • 07 May, 2021
  • 1 location
Camrelizumab With AC in Patients With Brain Metastases of Driven Gene-negative NSCLC

The primary hypothesis is that camrelizumab in combination with pemetrexed/ carboplatin will present a better efficacy for treatment of first line metastatic non-squamous non-small cell lung

pemetrexed
hormone therapy
metastasis
endocrine therapy
lung cancer
  • 1 views
  • 23 Jan, 2021
  • 1 location
Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC

-squamous non-small cell lung cancer

lung carcinoma
pemetrexed
squamous non-small cell lung cancer
osimertinib
EGFR
  • 0 views
  • 04 Sep, 2021
  • 1 location
Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC

This is a prospective, multicenter, open-label study to observe the effect of SBRT and immunotherapy combined with Bevacizumab or not in stage IV non-squamous non-small cell lung cancer (NSCLC

  • 0 views
  • 24 May, 2021
  • 1 location
Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations

The purpose of this study is to assess the safety and efficacy of pemetrexed + carboplatin + pembrolizumab (MK-3475) with lenvatinib (MK-7902/E7080) in patients with advanced nonsquamous non-small cell lung cancer harboring EGFR mutations.

  • 0 views
  • 24 Jul, 2022
  • 5 locations
PD1 and PARP for Maintenance Therapy in NSLLC

PARP inhibitor and PD1 in lung squamous cell carcinoma The current study will compare PD1 plus maintenance PARP for the treatment of squamous NSCLC. The study's 2 primary hypotheses are: respect

x-rays
fdg pet
measurable disease
chest x-ray
cancer
  • 0 views
  • 06 Jun, 2022
  • 1 location